Zurich-Schlieren, Switzerland, 2 November 2023
We are pleased to announce that TOPADUR PHARMA AG has been awarded an Innosuisse grant to fund our collaborative project with partners from Yonsei University and Juvic Inc. in South Korea. The project aims to develop new technologies for the treatment of systemic sclerosis. We thank Innosuisse and the Korea Institute for Advancement of Technology (KIAT) for their support.
The Switzerland Global Enterprise interviewed Reto Naef, CEO of TOPADUR PHARMA AG.
Read moreTopadur Pharma AG and Oshen Holdings SA Partner to Develop a Treatment for Alopecia
Read moreEMA grants TOP-N53 Orphan Drug Designation for the Treatment of Digital Ulcers in Systemic Sclerosis.
Read more